On Monday, Royalty Pharma plc (RPRX) stock saw a modest uptick, ending the day at $27.2 which represents a slight increase of $0.10 or 0.37% from the prior close of $27.1. The stock opened at $27.52 ...

Syndax Pharmaceuticals, a commercial-stage biopharmaceutical company, and Royalty Pharma plc, a largest buyer of biopharmaceutical royalties and a leading funder of innovation across the ...

To help foot the bill to launch its approved graft-versus-host disease drug Niktimvo and the expected launch of its leukemia treatment revumenib, Syndax has struck a $350 million licensing deal with ...

Royalty Pharma (RPRX) and Syndax Pharmaceuticals (SNDX) announced that Royalty Pharma has entered into a $350M synthetic royalty funding ...

Syndax Pharmaceuticals has entered a synthetic royalty funding agreement with Royalty Pharma, focused on US net sales of Niktimvo (axatilimab-csfr), a treatment for chronic graft-versus-host disease ...

Royalty Pharma (NASDAQ:RPRX – Get Free Report) was downgraded by stock analysts at StockNews.com from a “buy” rating to a ...

Royalty Pharma (NASDAQ:RPRX – Get Free Report) is scheduled to be posting its quarterly earnings results before the market opens on Wednesday, November 6th. Analysts expect Royalty Pharma to post ...

In its upcoming report, Royalty Pharma (RPRX) is predicted by Wall Street analysts to post quarterly earnings of $0.95 per share, reflecting an increase of 20.3% compared to the same period last year.

Syndax Pharmaceuticals Inc (SNDX) reports robust financials and strategic milestones, including FDA approvals and a ...

Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenibExpected to fund Syndax ...

Syndax Pharmaceuticals (Nasdaq: SNDX) and Royalty Pharma plc (Nasdaq: RPRX) today announced that Syndax has entered into a $350 million synthetic royalty funding agreement with Royalty Pharma based on ...

Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenibExpected to fund Syndax through profitability; proforma cash approaching $800 mil ...